[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. [2] MORGAN E, SOERJOMATARAM I, RUMGAY H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040:new estimates from GLOBOCAN 2020[J]. Gastroenterology, 2022, 163(3):649-658. [3] 赫捷, 陈万青, 李兆申, 等. 中国食管癌筛查与早诊早治指南(2022, 北京)[J]. 中国肿瘤, 2022, 31(6):401-436. [4] HUANG Y J, JIA M Z, YANG X Q, et al. Annexin A2:the diversity of pathological effects in tumorigenesis and immune response[J]. Int J Cancer, 2022, 151(4):497-509. [5] MA S, LU C C, YANG L Y, et al. ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis[J]. J Exp Clin Cancer Res, 2018, 37(1):183. [6] CONG L, RAN F A, COX D, et al. Multiplex genome engineering using CRISPR/Cas systems[J]. Science, 2013, 339(6121):819-823. [7] QI L S, LARSON M H, GILBERT L A, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression[J]. Cell, 2021, 184(3):844. [8] CHAVEZ M, CHEN X Y, FINN P B, et al. Advances in CRISPR therapeutics[J]. Nat Rev Nephrol, 2023, 19(1):9-22. [9] FIX S M, FORGET M A, SAKELLARIOU-THOMPSON D, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling[J]. J Immunother Cancer, 2022, 10(7):e003750. [10] GUPTA D, BHATTACHARJEE O, MANDAL D, et al. CRISPR-Cas9 system:a new-fangled dawn in gene editing[J]. Life Sci, 2019, 232:116636. [11] SANJANA N E, SHALEM O, ZHANG F. Improved vectors and genome-wide libraries for CRISPR screening[J]. Nat Methods, 2014, 11(8):783-784. [12] SHALEM O, SANJANA N E, HARTENIAN E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells[J]. Science, 2014, 343(6166):84-87. [13] LI Z N, YU L F, HU B H, et al. Advances in cancer treatment:a new therapeutic target, Annexin A2[J]. J Cancer, 2021, 12(12):3587-3596. [14] VALAPALA M, THAMAKE S I, VISHWANATHA J K. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events[J]. J Cell Sci, 2011, 124(Pt 9):1453-1464. [15] CUA S, TAN H L, FONG W J, et al. Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448[J]. Oncotarget, 2018, 9(17):13206-13221. [16] LEONG L, TAN H L, CUA S, et al. Preclinical activity of embryonic annexin A2-specific chimeric antigen receptor T cells against ovarian cancer[J]. Int J Mol Sci, 2020, 21(2):381. [17] LI Z F, PAN Y Z, YAO J Y, et al. ANXA2 as a novel substrate of FBXW7 promoting esophageal squamous cell carcinoma via ERK phosphorylation[J]. Biochem Biophys Res Commun, 2023, 649:93-100. [18] ZHANG F, WEN Y, GUO X. CRISPR/Cas9 for genome editing:progress, implications and challenges[J]. Hum Mol Genet, 2014, 23(R1):R40-R46. [19] GUO C T, MA X T, GAO F, et al. Off-target effects in CRISPR/Cas9 gene editing[J]. Front Bioeng Biotechnol, 2023, 11:1143157. [20] 崔婷婷. ANXA2敲除对结肠癌caco2细胞运动相关形态的研究[D]. 西安:陕西师范大学, 2012. [21] FUKUDA N, SENGA Y, HONDA S. Anxa2- and Ctsd-knockout CHO cell lines to diminish the risk of contamination with host cell proteins[J]. Biotechnol Prog, 2019, 35(4):e2820. |